预约演示
更新于：2025-06-23
Senaparib
塞纳帕利
更新于：2025-06-23
概要
基本信息
原研机构 |
在研机构 |
非在研机构- |
权益机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C24H20F2N6O3 |
InChIKeyVBTUJTGLLREMNW-UHFFFAOYSA-N |
CAS号1401682-78-7 |
关联
23
项与 塞纳帕利 相关的临床试验NCT06617923
A Phase 2 Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
NCT07019194
An Open-label, Randomized, Single-dose, Two-way Crossover Bioequivalence Study to Compare Two Strengths (10 mg and 20 mg) of Senaparib Capsules in Healthy Chinese Subjects Following Oral Administration Under Fasting Condition
NCT05824455
An Open, Multicenter, Phase Ib/II Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors
100 项与 塞纳帕利 相关的临床结果
登录后查看更多信息
100 项与 塞纳帕利 相关的转化医学
登录后查看更多信息
100 项与 塞纳帕利 相关的专利（医药）
登录后查看更多信息
10
项与 塞纳帕利 相关的文献（医药）2025-05-01JOURNAL OF CONTROLLED RELEASE
Multifunctional nanoparticle-mediated targeting of metabolic reprogramming and DNA damage response pathways to treat drug-resistant triple-negative breast cancer
Article
作者: Wang, Jue ; Wang, Cheng ; Cai, Zimin ; Sun, Chao ; Zhu, Sifeng ; Wu, Jibin ; Han, Xu
Multi-drug resistance and immunosuppressive triple-negative breast cancer (TNBC) is triggered by the Warburg effect, which promotes homologous recombination repair (HRR) and upregulates expression of P-glycoprotein (P-gp), in turn preventing DNA damage from chemotherapy and creating an immunosuppressive microenvironment. It is therefore of clinical relevance to develop an effective delivery system that targets metabolic reprogramming and DNA damage response pathways for the treatment of drug-resistant TNBC. Herein, a P-gp-inhibiting and GSH-responsive multifunctional drug carrier targeting integrin αvβ3 was synthesised for the delivery of Lonidamine-prodrug (M1, glycolysis inhibitor) and Senaparib (Se, Poly [ADP-ribose] polymerase inhibitor). The nanodrug delivery system (iPR@M1/Se nanoparticles) exhibit effective tumour penetration and P-gp inhibition, effectively inducing DNA damage and apoptosis in Olaparib-resistant TNBC cells in vitro, as well as a higher tumour inhibitory rate compared with that of Se (81.82 % ± 2.31 % vs 43.91 % ± 4.65 %) in vivo. Mechanistically, iPR@M1/Se nanoparticles not only reshaped the immunosuppressive microenvironment resulting from tumour glycolysis, but also downregulated the expression of HRR-related protein, fostering the cytoplasmic accumulation of DNA damage fragments, which induced activation of the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon gene (STING) pathway. Experimental results show that iPR@M1/Se nanoparticles effectively promote dendritic cell maturation and T lymphocyte activation, which elicits long-term immune memory responses, and prevents tumour recurrence and lung metastasis. Therefore, these multifunctional nanoparticles have great potential and provide a clinically relevant and valuable option for Olaparib-resistant TNBC.
2025-04-01JOURNAL OF BIOLOGICAL CHEMISTRY
Duplexed CeTEAM drug biosensors reveal determinants of PARP inhibitor selectivity in cells
Article
作者: Alam, Seher ; Rotili, Dante ; Altun, Mikael ; Lovric, Alen ; Fabbrizi, Emanuele ; Pires, Maria J ; Valerie, Nicholas C K
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) targeting PARP1 and PARP2 have revolutionized cancer therapy by selectively killing cancer cells with defective DNA repair. However, achieving PARP1 or PARP2-selective inhibitors is difficult due to structural homology. Selectivity profiling is typically done with purified proteins, but these lack the complexity of intracellular environments and could therefore be inaccurate. Here, we duplex PARP1 L713F-GFP and PARP2 L269A-mCherry cellular target engagement by accumulation of mutant (CeTEAM) drug biosensors to systematically characterize binding and cell cycle alterations of 27 PARPi. Our results reveal that most PARPi are equipotent for both PARPs, including the next-generation drug, senaparib. However, benzimidazole carboxamide (niraparib) derivatives demonstrated PARP1-selective tendencies, while phthalazinones (olaparib) favored PARP2. AZD5305, a reported PARP1-selective inhibitor with characteristics of both series, was the exception and appears ∼1600-fold more potent toward PARP1. In agreement with current understanding, we see that trapping-associated S/G2-phase transitions positively correlate with PARP1/2 binding potency, while some potent binders, such as veliparib, did not - likely reflecting their allosteric influence on DNA retention. We also assessed the effect of the PARP1/2 active site component, histone PARylation factor 1, on intracellular PARPi binding and see that its depletion elicits slight deviations in apparent binding potency, while contributing additively to trapping-like phenotypes. The PARP1/2 CeTEAM platform thus provides a structural roadmap for the development of selective PARPi and should facilitate the discovery of targeted therapies. Furthermore, our results highlight that multiplexing CeTEAM biosensors and layered genetic perturbations can systematically profile determinants of intracellular drug selectivity.
2025-01-02MOLECULAR CANCER THERAPEUTICS
The Discovery of a Potent PARP1 Inhibitor Senaparib
Article
作者: Guo, Mingchuan ; Cai, Sui X. ; Tian, Ye E. ; Jiang, Yangzhen ; Ma, Ning ; Wang, Xiaozhu
Abstract:
PARP1 is a critical enzyme involved in DNA damage repair. It belongs to a superfamily of proteins and catalyzes poly(ADP-ribosyl)ation (PARylation). PARP1 inhibitors are effective to treat tumors that have homologous recombination deficiency such as those with BRCA1/2 mutations. The PARP1 inhibitors that have been approved by FDA inhibit both PARP1 and PARP2. PARP2 has also been suggested to play a similar function in DNA repair as PARP1. In addition to inhibiting PARP1 enzymatic activities, PARP1 inhibitors cause the PARP1 enzyme to be “trapped” on DNA, stalling the DNA replication fork and eventually causing double-strand DNA breaks and cell death. Here, we report a PARP1 inhibitor, Senaparib, which has a novel chemical structure and high potency inhibiting PARP1/2 enzymes. Senaparib was highly potent in cell viability tests against tumor cells with BRCA1/2 mutations. It was efficacious in cell line-derived and patient-derived xenograft models in tumors harboring BRCA1/2 mutations. In combination studies, Senaparib used with temozolomide had shown strong synergistic cytotoxicity in both in vitro and in vivo experiments. Senaparib represents a novel class of PARP1 inhibitors that can be used for the treatment of cancer. A phase III clinical study of Senaparib for maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer has met its primary endpoint, and a new drug application of Senaparib has been accepted by the National Medical Products Administration of China for review.
110
项与 塞纳帕利 相关的新闻（医药）2025-05-30
·英派药业
ASCO会议临床结果临床1期AACR会议
2025-04-30
·英派药业
AACR会议临床2期临床结果临床1期
2025-04-02
·药事纵横
上市批准申请上市
100 项与 塞纳帕利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 输卵管癌 | 中国 | 2025-01-14 | |
| 卵巢上皮癌 | 中国 | 2025-01-14 | |
| 原发性腹膜癌 | 中国 | 2025-01-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 转移性去势抵抗性前列腺癌 | 临床2期 | 美国 | 2021-12-31 | |
| 转移性去势抵抗性前列腺癌 | 临床2期 | 中国 | 2021-12-31 | |
| 转移性去势抵抗性前列腺癌 | 临床2期 | 澳大利亚 | 2021-12-31 | |
| 晚期恶性实体瘤 | 临床2期 | 美国 | 2021-09-28 | |
| 晚期恶性实体瘤 | 临床2期 | 澳大利亚 | 2021-09-28 | |
| 晚期恶性实体瘤 | 临床2期 | 韩国 | 2021-09-28 | |
| 广泛期小细胞肺癌 | 临床2期 | 美国 | 2021-09-28 | |
| 广泛期小细胞肺癌 | 临床2期 | 澳大利亚 | 2021-09-28 | |
| 广泛期小细胞肺癌 | 临床2期 | 韩国 | 2021-09-28 | |
| 小细胞肺癌 | 临床2期 | 中国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 卵巢癌 BRCA1 Mutation | BRCA2 Mutation | 93 | 積繭繭築鑰襯衊膚鑰積(齋齋選醖顧積網積衊遞) = 鹹襯鹹糧積夢窪製夢窪 選醖範鏇鹽壓齋構獵壓 (艱願壓願範築夢鬱衊艱, 86.2 ~ 97.5) 更多 | 积极 | 2023-10-22 | ||
临床3期 | 卵巢癌 维持 | 404 | 積積選糧膚遞襯艱窪蓋(壓願憲簾糧鬱構鏇衊構) = 衊鹹鬱壓廠廠艱顧遞觸 簾積鑰憲選夢壓糧觸網 (艱築鏇築壓襯獵廠獵淵 ) 更多 | 积极 | 2023-10-20 | ||
Placebo | 積積選糧膚遞襯艱窪蓋(壓願憲簾糧鬱構鏇衊構) = 衊顧膚夢蓋餘繭襯夢積 簾積鑰憲選夢壓糧觸網 (艱築鏇築壓襯獵廠獵淵 ) 更多 | ||||||
临床3期 | 404 | 製醖築糧願餘願襯遞餘(鏇窪顧憲壓糧鑰鹽齋淵) = 鹽願襯築憲糧範齋簾範 獵壓積艱憲繭獵鑰構鑰 (衊願餘觸鹽積觸艱鹽鏇 ) | 积极 | 2023-09-28 | |||
Placebo | 製醖築糧願餘願襯遞餘(鏇窪顧憲壓糧鑰鹽齋淵) = 蓋構廠選積艱鹽憲夢築 獵壓積艱憲繭獵鑰構鑰 (衊願餘觸鹽積觸艱鹽鏇 ) | ||||||
临床1/2期 | 42 | 積夢觸膚遞觸遞餘鏇鬱(窪餘鹽範繭獵鑰獵壓製) = 淵構鏇網淵蓋壓鹽積獵 觸窪廠襯顧蓋顧廠膚鹽 (衊廠顧壓膚築糧鬱糧鏇, 5.4 ~ 28.5) 更多 | 积极 | 2023-09-12 | |||
(Platinum sensitive) | 積夢觸膚遞觸遞餘鏇鬱(窪餘鹽範繭獵鑰獵壓製) = 夢築膚選願遞鹹鬱獵鑰 觸窪廠襯顧蓋顧廠膚鹽 (衊廠顧壓膚築糧鬱糧鏇, 2.4 ~ 30.2) 更多 | ||||||
临床1期 | 57 | 糧廠鏇醖衊鏇積積淵鏇(膚鹹範淵鹹醖糧遞顧願) = 鏇憲遞鹽範窪選鏇鹹獵 鑰獵顧鏇窪鬱衊衊選糧 (鹽齋齋鑰淵鏇顧範醖鹽 ) 更多 | - | 2023-06-20 | |||
临床1期 | 39 | 簾鬱願鬱鏇願壓簾夢膚(願選餘襯構齋鬱願襯觸) = Most treatment-emergent adverse events were grade 1-2 (91%). Seven patients (17.9%) reported hematologic treatment-emergent adverse events. Treatment-related adverse events occurred in eight patients (20.5%), and the most frequent was nausea (7.7%). Two deaths were reported after the end of study treatment, one of which was considered a complication from senaparib-related bone marrow failure. 遞醖窪廠獵築壓艱壓膚 (鏇繭糧遞觸鬱壓簾鑰淵 ) | - | 2023-01-31 | |||
临床1期 | 14 | 憲餘積廠衊鬱繭鏇願窪(醖鑰築範鏇窪鹹衊築糧) = The MTD and RP2D were determined as: senaparib 80 mg plus temozolomide 20 mg. 窪鏇遞蓋鑰襯築鑰選積 (顧壓淵顧壓積鹹襯製糧 ) 更多 | 积极 | 2022-06-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用